Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2006 1
2007 2
2008 1
2011 1
2013 5
2014 1
2015 4
2016 8
2017 10
2018 11
2019 18
2020 5
2021 6
2022 2
2023 3
2024 2
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Mok TSK, et al. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955977 Clinical Trial.
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. N Engl J Med. 2020. PMID: 32905676 Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Selective Inhibitors of G2019S-LRRK2 Kinase Activity.
Garofalo AW, Bright J, De Lombaert S, Toda AMA, Zobel K, Andreotti D, Beato C, Bernardi S, Budassi F, Caberlotto L, Gao P, Griffante C, Liu X, Mengatto L, Migliore M, Sabbatini FM, Sava A, Serra E, Vincetti P, Zhang M, Carlisle HJ. Garofalo AW, et al. Among authors: beato c. J Med Chem. 2020 Dec 10;63(23):14821-14839. doi: 10.1021/acs.jmedchem.0c01243. Epub 2020 Nov 16. J Med Chem. 2020. PMID: 33197196
The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG).
Font A, Luque R, Villa JC, Domenech M, Vázquez S, Gallardo E, Virizuela JA, Beato C, Morales-Barrera R, Gelabert A, Maciá S, Puente J, Rubio G, Maldonado X, Perez-Valderrama B, Pinto A, Fernández Calvo O, Grande E, Garde-Noguera J, Fernández-Parra E, Arranz JÁ. Font A, et al. Among authors: beato c. Target Oncol. 2019 Feb;14(1):15-32. doi: 10.1007/s11523-019-00619-7. Target Oncol. 2019. PMID: 30694442 Review.
Risk stratification for clinical severity of pulmonary embolism in patients with cancer: a narrative review and MASCC clinical guidance for daily care.
Muñoz-Guglielmetti D, Cooksley T, Ahn S, Beato C, Aramberri M, Escalante C, Font C; Multinational Association of Supportive Care in Cancer (MASCC) Hemostasis Study Group. Muñoz-Guglielmetti D, et al. Among authors: beato c. Support Care Cancer. 2022 Oct;30(10):8527-8538. doi: 10.1007/s00520-022-07131-1. Epub 2022 May 17. Support Care Cancer. 2022. PMID: 35579753 Review.
Brain-penetrant cyanoindane and cyanotetralin inhibitors of G2019S-LRRK2 kinase activity.
Garofalo AW, Schwarz J, Zobel K, Beato C, Bernardi S, Budassi F, Caberlotto L, Gao P, Griffante C, Liu X, Migliore M, Qiao F, Sabbatini FM, Sava A, Zhang M, Carlisle HJ. Garofalo AW, et al. Among authors: beato c. Bioorg Med Chem Lett. 2023 Oct 15;95:129487. doi: 10.1016/j.bmcl.2023.129487. Epub 2023 Sep 19. Bioorg Med Chem Lett. 2023. PMID: 37734423
SEOM clinical guidelines on cardiovascular toxicity (2018).
Virizuela JA, García AM, de Las Peñas R, Santaballa A, Andrés R, Beato C, de la Cruz S, Gavilá J, González-Santiago S, Fernández TL. Virizuela JA, et al. Among authors: beato c. Clin Transl Oncol. 2019 Jan;21(1):94-105. doi: 10.1007/s12094-018-02017-3. Epub 2019 Jan 9. Clin Transl Oncol. 2019. PMID: 30627982 Free PMC article.
75 results